BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
Menu

Latest Pharma Insights



Cosmetics Weekly Trademark Review: July 16, 2019
Personal-care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3...
HBW Insight - July 22, 2019
German HTA Body Slams Lack Of 'Real Innovation'
Too many new drugs have the same mechanism of action, says Germany’s health technology appraisal institute, IQWiG.
Pink Sheet - July 22, 2019
The UK’s Path To Sustainable Biosimilars Is Paved With Challenges
Experts came together at the UK’s Westminster Health Forum to discuss the importance of healthy competition among biosimilar developers, pressing...
Pink Sheet - July 22, 2019
A New Definition: The EU Answer To Medicines Shortages?
What is a medicines shortage? The answer may seem obvious, but the fact that European regulators have only now come...
In Vivo - July 22, 2019
Could The Gut Cure Brain Disease?
Scientists now understand that there are multiple, bi-directional links between gut and brain. They are using this knowledge to develop...
In Vivo - July 22, 2019
Global Top Three Trade Places As Going Gets Tough, Especially In The US
Mylan has moved up to become the world’s leading generics, biosimilars and OTC player, according to Generics Bulletin’s newly compiled...
Pink Sheet - July 22, 2019
Global Industry Welcomes World Health Organization’s Call For Widespread Oral Contraceptive Rx-To-OTC Switch
The Global Self-Care Industry Federation (previously the WSMI) welcomes a call from the World Health Organization to make oral contraceptive...
HBW Insight - July 22, 2019
Inflection's Lead Series Boosts AUM's Oncology Pipeline
Asian oncology venture gains worldwide rights to novel molecule series from Inflection, giving a leg up to its global ambitions.
Pink Sheet - July 22, 2019
QUOTED. 22 July 2019. Ben Dastoli.
When US FDA investigator Ben Dastoli inspects a medical device company, he typically sees firms making the same process validation...
Medtech Insight - July 22, 2019

Interview: Mallinckrodt Deal Golden For Silence Therapeutics
The gene silencing specialist has signed a collaboration that CEO David Horn Solomon tells Scrip will help push Silence up...
Scrip - July 19, 2019
Servier Deal Termination Fails To Dent MacroGenics’ Flotetuzumab Optimism
The French firm has handed back rights to MacroGenics’ lead DART candidate flotetuzumab. Undaunted, MacroGenics is forging ahead with clinical...
Scrip - July 19, 2019
Servier Option Termination Fails To Dent MacroGenics’ Flotetuzumab Optimism
The French firm has handed back rights to MacroGenics’ lead DART candidate flotetuzumab. Undaunted, MacroGenics is forging ahead with clinical...
Scrip - July 19, 2019
Teva Fails To Unblock Route To Relistor Rival In US
A US district court has rejected Teva’s argument that a key US patent protecting Bausch’s Relistor methylnaltrexone-based constipation remedy is...
Scrip - July 19, 2019
Dainippon Closing In On Cell Therapy Specialist Cynata
Australian venture with Phase II-ready cell therapy in sights of Sumitomo Dainippon as Japanese firm looks to build regenerative medicine...
Scrip - July 19, 2019

German HTA Body Slams Lack Of 'Real Innovation'
Too many new drugs have the same mechanism of action, says Germany’s health technology appraisal institute, IQWiG.
Pink Sheet - July 22, 2019
The UK’s Path To Sustainable Biosimilars Is Paved With Challenges
Experts came together at the UK’s Westminster Health Forum to discuss the importance of healthy competition among biosimilar developers, pressing...
Pink Sheet - July 22, 2019
Global Top Three Trade Places As Going Gets Tough, Especially In The US
Mylan has moved up to become the world’s leading generics, biosimilars and OTC player, according to Generics Bulletin’s newly compiled...
Pink Sheet - July 22, 2019
Inflection's Lead Series Boosts AUM's Oncology Pipeline
Asian oncology venture gains worldwide rights to novel molecule series from Inflection, giving a leg up to its global ambitions.
Pink Sheet - July 22, 2019

A New Definition: The EU Answer To Medicines Shortages?
What is a medicines shortage? The answer may seem obvious, but the fact that European regulators have only now come...
In Vivo - July 22, 2019
Could The Gut Cure Brain Disease?
Scientists now understand that there are multiple, bi-directional links between gut and brain. They are using this knowledge to develop...
In Vivo - July 22, 2019

QUOTED. 22 July 2019. Ben Dastoli.
When US FDA investigator Ben Dastoli inspects a medical device company, he typically sees firms making the same process validation...
Medtech Insight - July 22, 2019

Cosmetics Weekly Trademark Review: July 16, 2019
Personal-care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3...
HBW Insight - July 22, 2019
Global Industry Welcomes World Health Organization’s Call For Widespread Oral Contraceptive Rx-To-OTC Switch
The Global Self-Care Industry Federation (previously the WSMI) welcomes a call from the World Health Organization to make oral contraceptive...
HBW Insight - July 22, 2019

Repligen nets $356.6mm through public sale of common shares and notes
Repligen Corp. (biologics bioprocessing) netted $356.6mm through concurrent public offerings of common shares and senior notes. The company sold 1.38mm common at $87, and also issued $250mm aggregate amount ($242.5mm net) of its 0.375% senior notes due 2024. The notes convert to common at a rate of 8.6749 common per $1k principal amount, or about $115.28 per share. (Repligen's stock averaged $85.47 at the time of the sales.)
Strategic Transactions - July 19, 2019
Back to the top Back to the top